Parexel’s Yen For Expansion Yields Acquisition Of Japanese Bridging Study Experts
This article was originally published in The Pink Sheet Daily
Deal worth $60 mil. could bring in business from firms seeking drug approval in Japan.
You may also be interested in...
Parexel is considering a strategic acquisition as it looks to utilize more than $100 mil. in excess cash
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.
Exec discusses the firm’s pulmonary arterial hypertension drug Tracleer and other endothelin receptor antagonists in Actelion’s pipeline.